twoplus fertility

Emerging

Singapore at-home fertility applicator for natural conception avoiding costly IVF/IUI; YC S20 $5.3M Monk's Hill Ventures-backed revenue-generating 2024 in SG/UK/US competing with Mosie Baby and Natalist for consumer fertility health products.

Updated March 2026

Company Overview

About twoplus fertility

Twoplus Fertility is a Singapore-based consumer fertility health company — backed by Y Combinator (S20) with $5.3 million raised including a $5.15 million seed round led by Monk's Hill Ventures in May 2022 — providing couples experiencing difficulty conceiving with at-home fertility products designed as non-invasive, affordable alternatives to clinical fertility treatments, starting with the Twoplus Sperm Guide applicator (an at-home cervical cap applicator that positions sperm closer to the cervix during natural conception attempts, increasing the probability of fertilization for couples with mild male factor infertility or unexplained subfertility). Founded in 2019 by Prusothman Raja and Benjamin Tee, Twoplus became revenue-generating in 2024 and distributes products in Singapore, the United Kingdom, and the United States.

Business Model & Competitive Advantage

Twoplus Fertility's product design addresses the accessibility and cost gap between over-the-counter fertility aids (ovulation tests, prenatal vitamins) and clinical fertility treatments (IUI starting at $1,000-3,000 per cycle, IVF starting at $10,000-20,000 per cycle): couples who have been trying to conceive for 6-12 months typically exhaust inexpensive interventions (timing intercourse, lifestyle changes) before the prohibitive cost of clinical fertility procedures drives them to 'try harder' with existing approaches rather than seek medical help. The Twoplus Applicator serves the intervention gap — a clinically informed, at-home device that improves natural conception odds for couples with mild male factor fertility challenges (low sperm count, reduced motility) or cervical mucus barriers by delivering sperm directly past the vaginal canal to the cervical os, replicating the first step of intrauterine insemination (IUI) without the clinic visit. The product launches in Singapore, UK, and US markets where fertility health consumer awareness is high and the customer acquisition cost for the fertility-aware demographic is manageable through digital health channels.

Competitive Landscape 2025–2026

In 2025, Twoplus Fertility competes in the consumer fertility, femtech, and at-home fertility treatment market with Mosie Baby (home insemination kit, acquired by Preseed), Natalist (fertility supplement and testing brand, acquired by Hers), and Legacy (male fertility testing, $25M raised) for consumer fertility product spending and digital health adoption. The global fertility treatment market ($24B+ in 2024, projected $38B by 2030) has significant consumer retail opportunity in the pre-clinical intervention tier — couples who will eventually pursue IVF but are looking for lower-cost interventions first represent a large addressable market that clinical fertility practices don't serve economically. Y Combinator S20 backing positioned Twoplus at the intersection of femtech and consumer health. Monk's Hill Ventures' Southeast Asia focus reflects the Singapore fertility health market opportunity and the APAC digital health distribution potential. The 2025 strategy focuses on growing the UK and US direct-to-consumer e-commerce channel, building the subscription model (monthly fertility wellness bundles combining the Applicator with supplements and cycle tracking), and pursuing regulatory clearances for the international market expansion.

Revenue
$5.3M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

twoplus fertility is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Not So Random Others

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

Decoda Health

Healthcare
HealthtechAi PoweredAutomationNorth America

Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap

Fortuna Health

Healthcare
HealthtechB2bAi PoweredAutomationNorth America

Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi

Brisk

Consumer Food & Beverage
B2cManufacturingNorth AmericaFortune500

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione

Altria

Consumer Goods
B2cManufacturingNorth AmericaPublicFortune500

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

For twoplus fertility

Claim This Profile

Are you from twoplus fertility? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim twoplus fertility Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention twoplus fertility vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →